Management of Heart Failure Patients with COVID-19: a Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.

Yuhui Zhang,Andrew J. S. Coats,Zhe Zheng,Marianna Adamo,Giuseppe Ambrosio,Stefan D. Anker,Javed Butler,Dingli Xu,Jingyuan Mao,Muhammad Shahzeb Khan,Ling Bai,Alexandre Mebazaa,Piotr Ponikowski,Qizhu Tang,Frank Ruschitzka,Petar Seferovic,Carsten Tschoepe,Shuyang Zhang,Chuanyu Gao,Shenghua Zhou,Michele Senni,Jian Zhang,Marco Metra

DOI: https://doi.org/10.1002/ejhf.1915

2020-01-01

European Journal of Heart Failure

Abstract:The coronavirus disease 2019 (COVID-19) pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is causing considerable morbidity and mortality worldwide. Multiple reports have suggested that patients with heart failure (HF) are at a higher risk of severe disease and mortality with COVID-19. Moreover, evaluating and treating HF patients with comorbid COVID-19 represents a formidable clinical challenge as symptoms of both conditions may overlap and they may potentiate each other. Limited data exist regarding comprehensive management of HF patients with concomitant COVID-19. Since these issues pose serious new challenges for clinicians worldwide, HF specialists must develop a structured approach to the care of patients with COVID-19 and be included early in the care of these patients. Therefore, the Heart Failure Association of the European Society of Cardiology and the Chinese Heart Failure Association & National Heart Failure Committee conducted web-based meetings to discuss these unique clinical challenges and reach a consensus opinion to help providers worldwide deliver better patient care. The main objective of this position paper is to outline the management of HF patients with concomitant COVID-19 based on the available data and personal experiences of physicians from Asia, Europe and the United States.